Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Trading Update

29 Jan 2018 07:00

RNS Number : 1235D
Sopheon PLC
29 January 2018
 

For Immediate Release

 

 

SOPHEON PLC

("Sopheon", the "Company" or the "Group")

 

TRADING UPDATE

 

Sopheon plc, the international provider of software and services for complete Enterprise Innovation Management solutions, is pleased to provide a further update on the Group's performance for the year ended 31 December 2017.

 

On 4 January 2018 we reported that continued momentum and market recognition had led to solid growth in 2017, with particular strength in the closing weeks of the year. Final quarter performance included signing two substantial deals, one in the USA and one in Germany, each with a multinational enterprise that is an undisputed leader in its field. These wins further validate the acceptance of our Accolade solution as a global platform, within some of the world's largest and most influential corporations. Volume of transactions was up, with 59 license deals recorded during the year compared to 49 in 2016. This includes three new SaaS (Software as a Service) customers, enhancing recurring revenue alongside the more traditional maintenance and hosting streams connected with our perpetual license sales.

 

The Board expects that reported revenues for the year ended 31 December 2017 will be over $28m, up from $23m in 2016, and comfortably ahead of current market expectations. The Board expects that both EBITDA and pre-tax profits will be significantly ahead of current market expectations. The year-end net cash position is expected to be $9.5m (2016: $4.2m).

 

In addition to its impact on 2017, the business performance described above contributes to a higher recurring revenue base going forward, a higher services backlog, and further license events driven by the fourth quarter signings. Overall revenue visibility* for 2018 already stands at $18m, compared to $13m at this time last year.

 

An important aspect of 2017 growth was the increased adoption of Accolade as an enterprise platform for areas outside our traditional innovation arena. Licenses sold in 2017 included applications for Accolade as diverse as capital expenditure management, IP management, IT project and portfolio management and enterprise initiativemanagement - each representing extension business beyond innovation. We believe our Accolade platform extension strategy represents a significant growth opportunity, and this will be a key area of investment in 2018.

 

Financial expectations noted above are subject to the completion of year-end financial close and audit processes. Sopheon intends to issue its results for the year ended 31 December 2017, on 22 March 2018.

 

For further information contact:

Barry Mence, ChairmanArif Karimjee, CFO

Sopheon plc

+ 44 (0) 1276 919 560

Carl Holmes / Giles Rolls (corporate finance)

Mia Gardener / Camille Gochez (corporate broking)

finnCap Ltd

+ 44 (0) 20 7220 0500

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete enterprise innovation management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 250 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. For more information, please visit www.sopheon.com

 

* Revenue visibility is defined on page 6 of our 2016 Annual Report

The information communicated in this announcement is inside information for the purposes of Article 7of Regulation 596/2014.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLDLFLVFFLBBF
Date   Source Headline
11th Apr 20167:00 amRNSDirectors Options and Shareholding
21st Mar 20167:00 amRNSAmendment to Terms of Convertible Loan Stock
17th Mar 20167:00 amRNSFinal Results
21st Jan 20168:29 amRNSAccolade Release 10.2
8th Jan 20167:00 amRNSTrading Update and Board Change
20th Oct 20159:33 amRNSDirector Dealing
19th Oct 20157:00 amRNSDirector Dealing
9th Oct 20153:41 pmRNSDirector Dealing
9th Oct 20151:12 pmRNSDirector Dealing
2nd Oct 20153:39 pmRNSDirector Dealing
23rd Sep 20157:00 amRNSAccolade Release 10.1
27th Aug 20157:01 amRNSHalf Yearly Report
1st Jul 20157:00 amRNSDirector Shareholding
10th Jun 20151:44 pmRNSResult of AGM
10th Jun 20157:00 amRNSAGM Statement
2nd Jun 20157:00 amRNSAccolade 10.0 release
15th May 20153:10 pmRNSNotice of AGM
7th May 201511:40 amRNSDIRECTOR SHAREHOLDING
23rd Apr 201511:10 amRNSDirector Shareholding
20th Apr 201511:43 amRNSDirector Shareholding
13th Apr 20152:03 pmRNSHolding(s) in Company
10th Apr 201511:05 amRNSHolding(s) in Company
8th Apr 20157:00 amRNSDELISTING FROM ALTERNEXT AMSTERDAM
19th Mar 20157:00 amRNSFinal Results
20th Feb 20157:00 amRNSSopheon Releases Accolade® 9.3
5th Feb 20154:12 pmRNSChange of Registered Office
28th Jan 20157:00 amRNSTrading Update
19th Dec 201410:30 amRNSResult of General Meeting
12th Dec 20143:00 pmRNSTrading Update
2nd Dec 20144:00 pmRNSProposed Share Subdivision
2nd Dec 20147:00 amRNSDirector/PDMR Shareholding
27th Oct 20144:15 pmRNSDirector/PDMR Shareholding
22nd Oct 20143:45 pmRNSDirector/PDMR Shareholding
21st Oct 20147:00 amRNSDirector/PDMR Shareholding
17th Oct 20141:50 pmRNSDirector/PDMR Shareholding
10th Oct 201411:15 amRNSResult of GM and Further re Share Consolidation
24th Sep 20147:00 amRNSAccolade 9.2 Release
12th Sep 20147:00 amRNSShare Consolidation
28th Aug 20147:00 amRNSHalf Yearly Report
11th Jun 201412:20 pmRNSResult of AGM
11th Jun 20147:00 amRNSAGM Statement
2nd Jun 20147:00 amRNSAmendment To The Terms Of Convertible Loan Stock
22nd May 20147:00 amRNSAlternext Amsterdam
1st May 20147:00 amRNSInterim Management Statement
22nd Apr 20147:01 amRNSSopheon Delivers Accolade Release 9.1
11th Apr 20147:00 amRNSWind Down Of Alternext Amsterdam
20th Mar 20147:01 amRNSTotal Voting Rights
20th Mar 20147:00 amRNSPreliminary Results
6th Mar 20147:00 amRNSNew Debt Facility
29th Jan 20148:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.